The
The patents, which are FDA Orange Book1 listed, provide additional protection to the NEXTSTELLIS formulation. Both newly listed patents are terminally disclaimed over the previously announced
NEXTSTELLIS is the first and only contraceptive pill featuring the new estrogen E4, in combination with the well-established progestin drospirenone. E4 is a native and tissue selective estrogen with distinct effects on breast tissues and the liver. Notably, E4 is naturally produced by the human fetus during pregnancy. The E4 in NEXTSTELLIS is produced from a plant source.
Mithra s commercialization partner,
Graham Dixon, Chief Scientific Officer of Mithra, stated, We are excited to have been granted additional patent coverage for ESTELLE under the trademark NEXTSTELLIS, an oral contraceptive with a novel estrogen, in
Contact:
Tel: +32 (0)4 349 28 22
Email: info@mithra.com
Tel: +32 (0)4 353 37 00
Email: info@mithracdmo.com
(C) 2024 Electronic News Publishing, source